Media stories about Bioverativ (NASDAQ:BIVV) have trended somewhat positive on Thursday, Accern Sentiment reports. The research firm identifies positive and negative press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Bioverativ earned a news impact score of 0.11 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 45.2265638138837 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the news articles that may have impacted Accern Sentiment’s analysis:
- Bioverativ (BIVV) Raised to “Outperform” at Cowen (americanbankingnews.com)
- Sanofi in talks with Advent to sell its European generics arm for €1.9bn (cityam.com)
- Peregrine Capital Management Llc Buys Lumentum Holdings Inc, Box Inc, Gates Industrial Corp PLC, Sells Bioverativ … (gurufocus.com)
- Bioverativ Highlights the Impact of Humanitarian Aid in Hemophilia (businesswire.com)
- $0.27 EPS Expected for Delta Apparel, Inc. (DLA); Bioverativ (BIVV) Shorts Down By 76.05% (mtastar.com)
BIVV stock traded up $0.33 during mid-day trading on Thursday, reaching $104.98. The company’s stock had a trading volume of 792,900 shares, compared to its average volume of 3,027,685. Bioverativ has a fifty-two week low of $48.14 and a fifty-two week high of $105.01.
A number of research firms have commented on BIVV. Zacks Investment Research upgraded shares of Bioverativ from a “hold” rating to a “buy” rating and set a $62.00 price objective for the company in a report on Monday, January 8th. William Blair reiterated a “hold” rating on shares of Bioverativ in a report on Thursday, March 8th. Royal Bank of Canada increased their price objective on shares of Bioverativ to $68.00 and gave the company a “market perform” rating in a report on Thursday, January 18th. Jefferies Group increased their price objective on shares of Bioverativ to $79.00 and gave the company a “buy” rating in a report on Thursday, January 18th. Finally, Raymond James downgraded shares of Bioverativ from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 23rd. Twelve analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $64.70.
ILLEGAL ACTIVITY WARNING: This piece of content was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece of content can be viewed at https://stocknewstimes.com/2018/04/19/bioverativ-bivv-getting-somewhat-favorable-press-coverage-analysis-finds.html.
Bioverativ Company Profile
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Receive News & Ratings for Bioverativ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ and related companies with MarketBeat.com's FREE daily email newsletter.